Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance

Molecular Pharmacology

Volumn 64, Issue 2, 2003, Pages 279-288

  Wierdl, Monika ^a   Wall, Amelia ^a   Morton, Christopher L ^a   Sampath, Janardhan ^a   Danks, Mary K ^a   Schuetz, John D ^a   Potter, Philip M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN DERIVATIVE; CARBOXYLESTERASE; COMPLEMENTARY DNA; CORYNANTHEINE; CREMOPHOR; CYCLOSPORIN A; HOE 33342; IRINOTECAN; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE D4; MITOXANTRONE; PROBENECID; PROGESTERONE; PROSTAGLANDIN A1; PROTEIN INHIBITOR; PSE 833; RESERPINE; TOMELUKAST; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VERLUKAST; YOHIMBINE;

ANIMAL CELL; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL GROWTH; CELL PROTECTION; COLON CANCER; DRUG ACCUMULATION; DRUG ACTIVATION; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME INHIBITION; GENE DELIVERY SYSTEM; GENE MUTATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; LIVER; LUNG CANCER; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SENSITIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; BENZIMIDAZOLES; BIOLOGICAL TRANSPORT; CAMPTOTHECIN; CARBOXYLIC ESTER HYDROLASES; CELL DIVISION; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM PROTEINS; RABBITS; TUMOR CELLS, CULTURED;

EID: 0042343743     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.2.279     Document Type: Article

References (37)

1. Allen JD, Jackson SC, and Schinkel AH (2002) A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. Cancer Res 62:2294-2299.
2. Allikmets R, Schriml LM, Hutchinson A, Romano Spica V, and Dean M (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58:5337-5539.
3. Baker L, Khan R, Lynch T, Savaraj N, Sandler A, Feun L, Schaser R, Hanover C, and Petit R (1997) Phase II study of irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC) (Abstract). Proceedings of the American Society for Clinical Oncology 16:1658.
4. Bates SE, Robey R, Miyake K, Rao K, Ross DD, and Litman T (2001) The role of half-transporters in multidrug resistance. J Bioenerg Biomembr 33:503-511.
5. Beaufay H, Amar-Costesec A, Feytmans E, Thines-Sempoux D, Wibo M, Robbi M, and Berthet J (1974) Analytical study of microsomes and isolated subcellular membranes from rat liver. I. Biochemical methods. J Cell Biol 61:188-200.
6. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, and Gonzalez C (1996) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709-715.
7. Danks MK, Morton CL, Krull EJ, Cheshire PJ, Richmond LB, Naeve CW, Pawlik CA, Houghton PJ, and Potter PM (1999) Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin Cancer Res 5:917-924.
8. Danks MK, Morton CL, Pawlik CA, and Potter PM (1998) Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Cancer Res 58:20-22.
9. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670.
10. Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LC, Ma MK, Hoffer FA, Meyer WH, et al. (1999) Direct translation of a protracted irinotecan schedule from a xenograft model to a Phase I trial in children. J Clin Oncol 17:1815-1824.
11. Guichard S, Morton CL, Krull EJ, Stewart CF, Danks MK, and Potter PM (1998) Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase. Clin Cancer Res 4:3089-3094.
12. Higgins CF (2001) ABC transporters: physiology, structure and mechanism, an overview. Res Microbiol 152:205-210.
13. Honjo Y, Hrycyna CA, Yan QW, Medina Perez WY, Robey RW, van de Laar A, Litman T, Dean M, and Bates SE (2001) Acquired mutations in the MXP/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61:6635-6639.
14. Keppler D, Jedlitschky G, and Leier I (1998) Transport function and substrate specificity of multidrug resistance protein. Methods Enzymol 292:607-616.
15. Khanna R, Morton CL, Danks MK, and Potter PM (2000) Proficient metabolism of CPT-11 by a human intestinal carboxylesterase. Cancer Res 60:4725-4728.
16. Komatani H, Kotani H, Hara Y, Nakagawa R, Matsumoto M, Arakawa H, and Nishimura S (2001) Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res 61:2827-2832.
17. Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, Furuse K, and Fukuoka M (1998) Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 16:1068-1074.
18. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, and Bates SE (2000) The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113:2011-2021.
19. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
20. Meck M, Wierdl M, Wagner L, Burger R, Harris LC, Potter PM, and Danks MK (2001) A VDEPT approach to purging neuroblastoma cells from hematopoeitic cells using adenovirus encoding rabbit carboxylesterase and CPT-11. Cancer Res 61:5083-5089.
21. Morton CL, Wadkins RM, Danks MK, and Potter PM (1999) CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res 59:1458-1463.
22. Morton CL, Wierdl M, Oliver L, Ma M, Danks MK, Stewart CF, Eiseman JL, and Potter PM (2000) Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res 60:4206-4210.
23. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, and Sarkadi B (2001) Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 285:111-117.
24. Potter PM, Pawlik CA, Morton CL, Naeve CW, and Danks MK (1998a) Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug Irinotecan (CPT-11). Cancer Res 52:2646-2651.
25. Potter PM, Wolverton JS, Morton CL, Wierdl M, and Danks MK (1998b) Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme. Cancer Res 58:3627-3632.
26. Renes J, de Vries EE, Hooiveld GJ, Krikken I, Jansen PL, and Muller M (2000) Multidrug resistance protein MRP1 protects against the toxicity of the major lipid peroxidation product 4-hydroxynonenal. Biochem J 350:555-561.
27. Rocchi E, Khodjakov A, Volk EL, Yang CH, Litman T, Bates SE, and Schneider E (2000) The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem Biophys Res Commun 271:42-46.
28. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, and Nagai E (1994) Metabolic activation of CPT-11, 7-ethyl-10[4-(1-piperidino)-1-piperidino]carbonyloxycamptethecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 17:662-664.
29. Tanizawa A, Fujimori A, Fujimori Y, and Pommier Y (1994) Comparison of topoisomerase I inhibition, DNA damage and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86:836-842.
30. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, and Hori R (1992) Human P-glycoprotein transports cortisol, aldosterone and dexamethasone, but not progesterone. J Biol Chem 267:24248-24252.
31. Van Hattum AH, Schluper HM, Hausheer FH, Pinedo HM, and Boven E (2002) Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance. Int J Cancer 100:22-29.
32. Wagner LM, Guichard SM, Burger RA, Morton CL, Straign CM, Ashmun RA, Harris LC, Houghton PJ, Potter PM, and Danks MK (2002) Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients. Cancer Res 62:5001-5007.
33. Wierdl M, Morton CL, Harris LC, Danks MK, Schuetz JD, and Potter PM (2003) p53-Mediated regulation of expression of a rabbit liver carboxylesterase confers sensitivity to CPT-11. J Pharmacol Exp Ther 304:699-705.
34. Wierdl M, Morton CL, Weeks JK, Danks MK, Harris LC, and Potter PM (2001) Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res 61:5078-5082.
35. Yang CP, Cohen D, Greenberger LM, Hsu SI, and Horwitz SB (1990) Differential transport properties of two mdr gene products are distinguished by progesterone. J Biol Chem 265:10282-10288.
36. Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, and Schuetz EG (2003) Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13:19-28.
37. Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, and Sorrentino BP (2002) Bcrp1 gene expression is required for normal numbers of side population stem cells in mice and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci USA 99:12339-12344.